Lucid Lane, a Los Altos, Calif.-based telehealth solution for people with medication dependence and substance-use disorders, raised $16m in Series A funding.
The round was led by Accel with participation from Battery Ventures, AME Cloud Ventures, Morado Ventures and strategic angel investors. In conjunction with the funding, Eric Wolford, Partner at Accel, has joined the Lucid Lane board of directors.
The company intends to use the funds to continue to expand operations, development efforts and its business reach.
Led by Adnan Asar, co-founder and CEO, Lucid Lane uses data-driven personalized health planning, real-time interventions, daily coach-based support and daily on-going access to therapist support to support people with medication dependence and substance-use disorder. The solution is a core set of technologies and services that provide ongoing measurement and monitoring, personalized treatment planning and timely interventions.
The company also announced several product advancements, including its analytics engine that delivers personalized and context-sensitive treatment and support in real time. It has also expanded its services in order to address a wider spectrum of needs.
Lucid Lane is currently engaged in additional peer-reviewed, evidence-based, clinical trials at academic institutions, including Stanford University, the United States Veteran Affairs System, The University of Texas Health Science Center, Houston, and The University of Texas MD Anderson Cancer Center.